{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:16Z","timestamp":1791581896441,"version":"4.3.4"},"reference-count":27,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Oral squamous cell carcinoma (OSCC) is one of the most common types of cancer in the head and neck region. In advanced stages of OSCC, chemotherapy is commonly used for treatment, despite some cancer cells having low sensitivity to anticancer drugs. We focused on RBM17\/SPF45 as an essential drug-sensitizing factor in the context of malignant cells acquiring chemoresistance. Here, we demonstrate how RBM17 affects anticancer drug resistance in OSCC and we suggest the possible mechanism underlying its effects. After exposing oral cancer cell lines to fluorouracil (5-FU) and cisplatin, but not paclitaxel, the gene and protein expression of RBM17 increased. We found that siRNA-mediated RBM17-knockdown of the cell lines gained a significantly higher sensitivity to 5-FU, which was remarkably followed by a decrease in the expression of checkpoint kinase 1 (CHEK1) protein, whereas treatment with a CHEK1 inhibitor did not affect RBM17 protein expression in the oral cancer cell lines. These results indicate that RBM17 is a factor involved in the development of resistance to cytotoxic chemotherapy. We propose the underlying mechanism that RBM17 promotes CHEK1 protein expression in the ATM\/ATR pathway, triggering the development of chemoresistance in cancer cells.<\/jats:p>","DOI":"10.3390\/ijms26073127","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:36:49Z","timestamp":1743169009000},"page":"3127","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["RBM17 Promotes the Chemoresistance of Oral Squamous Cancer Cells Through Checkpoint Kinase 1"],"prefix":"10.3390","volume":"26","author":[{"given":"Miyuka","family":"Nakahara","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3905-9962","authenticated-orcid":false,"given":"Ryosuke","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4860-9508","authenticated-orcid":false,"given":"Isao","family":"Tokuoka","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3491-4500","authenticated-orcid":false,"given":"Kazuhiro","family":"Fukumura","sequence":"additional","affiliation":[{"name":"Oncology Innovation Center, Fujita Health University, Toyoake 470-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-550X","authenticated-orcid":false,"given":"Akila","family":"Mayeda","sequence":"additional","affiliation":[{"name":"Oncology Innovation Center, Fujita Health University, Toyoake 470-1192, Japan"},{"name":"xFOREST Therapuetics, Co., Ltd., Kyoto 602-0841, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-7228","authenticated-orcid":false,"given":"Masakazu","family":"Yashiro","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.3390\/curroncol30040283","article-title":"Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature","volume":"30","author":"Badwelan","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_2","unstructured":"The Global Cancer Observatory, IARC, and WHO (2024, August 02). Lip, Oral Cavity Cancer. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/1-lip-oral-cavity-fact-sheet.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104662","DOI":"10.1016\/j.oraloncology.2020.104662","article-title":"Management of locally advanced oral cancers","volume":"105","author":"Dhar","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.ejca.2015.08.007","article-title":"Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis","volume":"51","author":"Marta","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/1700","article-title":"Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex","volume":"20","author":"Neubauer","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nsmb1260","article-title":"U2AF-homology motif interactions are required for alternative splicing regulation by SPF45","volume":"14","author":"Corsini","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1038\/s41467-021-24879-y","article-title":"SPF45\/RBM17-dependent, but not U2AF-dependent, splicing in a distinct subset of human short introns","volume":"12","author":"Fukumura","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113534","DOI":"10.1016\/j.celrep.2023.113534","article-title":"SAP30BP interacts with RBM17\/SPF45 to promote splicing in a subset of human short introns","volume":"42","author":"Fukumura","year":"2023","journal-title":"Cell Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0002-9440(10)63538-9","article-title":"Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells","volume":"163","author":"Sampath","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20230669","DOI":"10.1515\/med-2023-0669","article-title":"Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells","volume":"18","author":"Wang","year":"2023","journal-title":"Open Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1996318","DOI":"10.1080\/23723556.2021.1996318","article-title":"SPF45\/RBM17-dependent splicing and multidrug resistance to cancer chemotherapy","volume":"8","author":"Fukumura","year":"2021","journal-title":"Mol. Cell Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/0008-5472.CAN-03-3675","article-title":"Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators","volume":"65","author":"Perry","year":"2005","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","article-title":"DNA-damaging agents in cancer chemotherapy: Serendipity and chemical biology","volume":"20","author":"Giaever","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: Mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12032-023-02138-y","article-title":"Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role","volume":"40","author":"Kannampuzha","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2013","journal-title":"Cell Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/IGC.0000000000000014","article-title":"Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary","volume":"24","author":"Itamochi","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lodovichi, S., Cervelli, T., Pellicioli, A., and Galli, A. (2020). Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186684"},{"key":"ref_22","first-page":"57","article-title":"Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines","volume":"53","author":"Kaneda","year":"2006","journal-title":"J. Med. Dent. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ando, K., Nakamura, Y., Nagase, H., Nakagawara, A., Koshinaga, T., Wada, S., and Makishima, M. (2019). Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153700"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_27","unstructured":"Broad DepMap (2024). Figshare+, DepMap 24Q2 Public. Dataset."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:21Z","timestamp":1760029461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26073127"],"URL":"https:\/\/doi.org\/10.3390\/ijms26073127","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}